ReviewBioactive materials2026
Learn from nature: Biomimetic nanocarriers for intracellular protein delivery.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nature-Inspired Solutions: Biomimetic Materials and Adaptive Devices for Precision Urinary Oncology.Cancers · 2026Review
- Self-Assembling Short Peptide Carriers for Gene Delivery.International journal of molecular sciences · 2026Review
- Cationic lipid-based nanoparticles for therapeutic delivery in cancer treatment: physicochemical characteristics, therapeutic cargos, and clinical potential.Applied microscopy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanocarriers have been regarded as the most potential therapeutic weapons to combat tumors and genetic diseases using protein drugs. However, nanocarriers often face many challenges during the delivery process. Due to the existence of cell membrane barriers, nanocarriers may be restricted extracellularly or degraded in lysosomes, thus unable to effectively deliver drugs to the target location. The biomimetic nanocarrier delivery systems have demonstrated unique advantages in the field of protein delivery. This review focuses on cutting-edge technologies such as biomimetic mineralized nanoparticles, Virus-like particles, and bacterium-like nanoparticles. These biomimetic nanocarriers exhibit great potential to bypass endocytosis and lysosomal restrictions due to their unique biomimetic properties. Additionally, this review reviews the latest progress of cytosolic protein drug delivery systems based on biomimetic systems in various medical research and clinical applications, including clinical targeted delivery, tumor therapy, and gene editing. It also compares the capabilities and limitations of these biomimetic cytosolic protein delivery systems with traditional nanocarriers, including factors that affect protein delivery efficiency, and emphasizes their potential to adopt targeted, sustainable, and minimally invasive treatment methods. Finally, this review proposes the current limitations and future research directions of protein delivery systems, expecting to provide more efficient solutions for disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.